Key clinical point: Biologics are underprescribed in the elderly, despite evidence that the efficacy of biologics is comparable between older and younger patients over time.
Major finding: Biologics were used more frequently in younger patients, but response rates to systemic therapies, including nonbiologics, were generally comparable between the elderly and controls.
Study details: An analysis of patient data in German and Swiss psoriasis registries, including approximately 765 individuals aged 65 years or older and 4,600 younger patients.
Disclosures: The PsoBest registry is sponsored by CVderm, DDG, and BVDD. The Swiss registry is supported by Janssen, AbbVie, Pfizer, Celgene, Lilly, and Novartis. Dr. Augustin did not provide disclosure information.
REPORTING FROM WCD2019